Group items tagged

This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies.

Centers for Disease Control and Prevention (CDC) supports a variety of activities in health departments and organizations aimed at preventing and controlling cancer, the second leading cause of death in US men and women. Since the passage of the Cancer Registries Amendment Act in 1992, the National Program of Cancer Registries (NPCR) has collected data on cancer occurrence, extent, treatment and outcomes in over 45 states and jurisdictions, representing 96% of the US population. CDC's Division of Cancer Prevention and Control (DCPC) has supported successful partnerships with national organizations to define standardized practices in U.S. cancer surveillance and assure and complete, timely, and high-quality data for the official federal U.S. Cancer Statistics. The purpose of this funding opportunity is to build strong partnerships among national organizations involved directly in cancer surveillance in order to enhance the data quality and operational efficiency of CDC’s National Program of Cancer Registries (NPCR). This program has three essential components: 1) Education, Translation and Quality Control of cancer surveillance standards and best practices; 2) Cancer Staging Collaboration and Support; and 3) Standardization and Support for Laboratory and Biomarker Electronic Reporting. The overarching goal of this project is to collaboratively define and promote uniform standards in cancer staging, collection and reporting. Funded entities will identify specific enhancement needs of cancer registries and support cancer surveillance professionals, including reporters (e.g. facilities, labs), tumor registrars, and registries to submit high quality, standardized data via central cancer registries to NPCR. Relevant performance measures will be used to assess the recipients’ activities that enhance the standards, quality, and operations of NPCR cancer surveillance system.

As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcriptome sequencing are available for tumor or affected tissue when justified. These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as "chemobrain." A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

The purpose of the Administrative Supplements for Collaborative Activities to Promote Cachexia Research is to support collaborative, multidisciplinary basic and translational research that addresses an important question in cancer cachexia and to expand the cadre of investigators experienced in cancer cachexia study design, model systems and data interpretation. These supplement applications must propose a collaboration between cancer researchers and researchers with documented expertise in cachexia research. The parent grant for the supplement must have an NCI primary assignment. Overall, the long-term goal of this supplement program is to encourage a focused examination of the biology of cancer cachexia and its effect on organs and systems beyond the tumor site(s). Applicants are strongly encouraged to discuss potential requests with the NCI scientific contacts listed below.

The purpose of the Administrative Supplements for Collaborative Activities to Promote Cachexia Research is to support collaborative, multidisciplinary basic and translational research that addresses an important question in cancer cachexia and to expand the cadre of investigators experienced in cancer cachexia study design, model systems and data interpretation. These supplement applications must propose a collaboration between cancer researchers and researchers with documented expertise in cachexia research. The parent grant for the supplement must have an NCI primary assignment. Overall, the long-term goal of this supplement program is to encourage a focused examination of the biology of cancer cachexia and its effect on organs and systems beyond the tumor site(s).

Also Listed under U01, U54, P01, & P50. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded U01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.   

The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded R01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.   

As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcriptome sequencing may be available for tumor or affected tissue when justified. These data, and associated clinical and phenotypic data, will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to currently funded NCI Specialized Center--Cooperative Agreements that will inform on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.

We encourage applications from innovators working in all aspects of pediatric oncology, pediatric surgical care, and influenza. Specific areas of focus include: Pediatric Oncology -Innovations in pediatric oncology port technologies -Drugs that target pediatric-specific driver genes -Bedside, rapid tumor genetic testing Pediatric Surgical Care -Pediatric-specific implants for trauma & fracture care including growth-enabling spine & trauma orthopedic implants -Innovative treatment options for adolescent idiopathic scoliosis -Surgical robotics to treat pediatric patients Influenza -Pediatric-focused innovations in influenza -Novel solutions for influenza vaccine delivery -Influenza pre-exposure including antivirals prophylaxis formulation Applications will be accepted across: -Pharmaceuticals -Medical devices -Consumer products -Global public health -Health technologies -Cross-sector initiatives (an integration of one or more areas of focus mentioned above) Submissions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria: -Potential impact -Uniqueness of solution & level of competition in the current market -Quality & feasibility of the technology -Team credibility & capabilities -Plans for utilizing JLABS @ Washington, DC

The AACR-Bayer Stimulating Therapeutic Advances through Research Training (START) Grants represent an exciting initiative to encourage and support collaboration between academia and industry. This novel model provides support for three years to postdoctoral and clinical research fellows working on a mentored cancer research project and includes one year spent on site at a Bayer facility. The combined academic and industry training provided through this program will be invaluable to young investigators, allowing them to attain a comprehensive research experience. Projects must have direct applicability and relevance to clinical translation and development in solid tumors and hematologic malignancies.

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.

A major focus of the Network must be placed on the acquisition and distribution of specimens in limited supply, such as: * Castration-resistant disease, metastatic disease, primary untreated "de novo" metastatic disease as defined by STAMPEDE or high-risk disease defined by CHAARTED, tumors of the aggressive variant phenotype * Disproportionately affected populations, defined by ethnicity or health service access (safety net, rural, settings) * Active surveillance populations * Longitudinal/sequential specimens The Network must also collect, store, and manage data derived from the distributed biospecimens, including images of the hematoxylin and eosin (H&E)-stained samples. Applications should describe how the development of the Network biorepository will enable the prostate cancer research community to address the FY17 PCRP Overarching Challenges and FY17 PCRP Focus Areas by utilizing Network biospecimens. Applications should propose a clearly defined mission that will guide the proposed Network's biospecimen collection, distribution, and data collection processes. The Network will consist of three to five Pathology Resource Sites and a Coordinating Center, which will also function as one of the Pathology Resource Sites. These organizations will be jointly responsible for developing and maintaining the biorepository for prostate cancer research.

This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies. Also Listed under (R21)

This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in naïve and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving naïve and drug resistant cancer cells toward effective cell death.

The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in nave and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving nave and drug resistant cancer cells toward effective cell death.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.